REFERENCES
1 Phelan AL, Katz R, Gostin LO. The Novel Coronavirus Originating in Wuhan, China: Challenges for Global Health Governance. JAMA.2020; (published online Jan 30.) DOI: 10.1001/jama.2020.1097. 2 Chan JW, Ng CK, Chan YH, et al. Short term outcome and risk factors for adverse clinical outcomes in adults with severe acute respiratory syndrome (SARS). Thorax. 2003;58(8):686–689. 3 Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet.2020;395(10223):507–513. 4 Miller A, Reandelar MJ, Fasciglione K, Roumenova V, Li Y, Otazu GH. Correlation between universal BCG vaccination policy and reduced morbidity and mortality for COVID-19: an epidemiological study.BioRxiv. 2020. DOI: 10.1101/2020.03.24.20042937. 5https://covid19bilgi.saglik.gov.tr/depo/rehberler/COVID-19_Rehberi.pdf. (Date accessed: May 20; 2020) 6 Summary of the WHO Position Paper on BCG vaccines: WHO position paper – February, 2018.https://www.who.int/immunization/policy/position_papers/PP_BCG_summary_2018.pdf. (Date accessed: May 20; 2020) 7 O’Neill LAJ, Netea MG. BCG-induced trained immunity: can it offer protection against COVID-19? Nat Rev Immunol. 2020; 20(6):335‐337. 8 Stensballe LG, Nante E, Jensen IP, et al. Acute lower respiratory tract infections and respiratory syncytial virus in infants in Guinea-Bissau: a beneficial effect of BCG vaccination for girls community based case-control study. Vaccine.2005;23(10):1251–1257. 9 Nemes E, Geldenhuys H, Rozot V, et al. Prevention of M. tuberculosis Infection with H4:IC31 Vaccine or BCG Revaccination. N Engl J Med. 2018;379(2):138–149. 10 Berg MK, Yu Q, Salvador CE, Melani I, Kitayama S. Mandated Bacillus CalmetteGuérin (BCG) vaccination predicts flattened curves for the spread of COVID-19. MedRxiv. 2020. DOI:10.1101/2020.04.05.20054163. 11 Singh BR, Gandharva R, Karthikeyan R, et al. Epidemiological Determinants of Acute Respiratory Syndrome Coronavirus-2 Disease Pandemic and The Role of the Bacille-Calmette-Guerin Vaccine in Reducing Morbidity and Mortality, J Pure Appl Microbiol. 2020; 14(Spl Edn.):6224. 12 Hizel K, Maral I, Karakus R, Aktas F. The influence of BCG immunisation on tuberculin reactivity and booster effect in adults in a country with a high prevalence of tuberculosis. Clin Microbiol Infect. 2004;10(11):980–983. 13 Eskiocak M, Marangoz B. Türkiye’de Bağışıklama Hizmetlerinin Durumu.http://www.ttb.org.tr/kutuphane/turkiyede_bagisiklama.pdf. (Date accessed: May 20; 2020) 14 Hensel J, McAndrews KM, McGrail DJ, Dowlatshahi DP, LeBleu VS, Kalluri R. Exercising caution in correlating COVID-19 incidence and mortality rates with BCG vaccination policies due to variable rates of SARS CoV-2 testing. MedRxiv. 2020; (published online April 11.) DOI: 10.1101/2020.04.08.20056051. 15 Hamiel U, Kozer E, Youngster I. SARS-CoV-2 Rates in BCG-Vaccinated and Unvaccinated Young Adults. JAMA. 2020;323(22):2340–2341. 16 Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. JAMA. 2020;(published online Feb 24.) DOI:10.1001/jama.2020.2648. 17 CDC COVID-19 Response Team. Preliminary Estimates of the Prevalence of Selected Underlying Health Conditions Among Patients with Coronavirus Disease 2019 - United States, February 12-March 28, 2020. MMWR Morb Mortal Wkly Rep 2020;69(13):382–386. 18 Chen T, Wu D, Chen H, et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. BMJ.2020;368:m1091. 19 Onder G, Rezza G, Brusaferro S. Case-Fatality Rate and Characteristics of Patients Dying in Relation to COVID-19 in Italy.JAMA. 2020; (published online Mar 23.) DOI: 10.1001/jama.2020.4683. 20 Wang D, Hu B, Hu C, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA. 2020;323(11):1061–1069. 21 Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet.2020;395(10223):507–513. 22 Verity R, Okell LC, Dorigatti I, et al. Estimates of the severity of coronavirus disease 2019: a model-based analysis. Lancet Infect Dis. 2020; (published online March 30.) DOI:10.1016/S1473-3099(20)30243-7S1473-3099(20)30243–7. 23 CDC COVID-19 Response Team. Severe Outcomes Among Patients with Coronavirus Disease 2019 (COVID-19) - United States, February 12-March 16, 2020. MMWR Morb Mortal Wkly Rep. 2020;69(12):343–346. 24 Gold JAW, Wong KK, Szablewski CM, et al. Characteristics and Clinical Outcomes of Adult Patients Hospitalized with COVID-19- Georgia, March 2020. MMWR Morb Mortal Wkly Rep. 2020;69(18):545–550. 25 Garg S, Kim L, Whitaker M, et al. Hospitalization Rates and Characteristics of Patients Hospitalized with Laboratory-Confirmed Coronavirus Disease 2019-COVID-NET, 14 States, March 1-30, 2020.MMWR Morb Mortal Wkly Rep. 2020;69(15):458–464.